Compare Teladoc Health Inc (TDOC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs GeneDx Holdings Corp — how do they compare? Teladoc Health Inc trades at $5.77 (market cap $1.01B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2× Teladoc Health Inc's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 4,668,477). Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and GeneDx Holdings Corp for 19 Days on average.
| TDOC | WGS | |
|---|---|---|
Market Cap | $1.01B | $2.02B |
Volume | 4,668,477 | 734,640 |
Sector | Health | Health |
52-Week High | $9.72 | $167.51 |
52-Week Low | $4.47 | $34.51 |
Typical Hold Time | 39 Days | 19 Days |
Enterprise Value | $1.27B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TDOC trades at $5.54, down 0.36% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $2.53B in 2025 but a net loss of $200.32M, reflecting ongoing profitability challenges. Analyst consensus is a 'Hold' with a $8.83 price target, indicating potential upside. Recent news includes a CFO transition and legal investigations, adding to investor uncertainty.
The outlook remains cautious due to persistent losses and competitive pressures, though valuation metrics like P/S of 0.4 and EV/EBITDA of 5.89 suggest the stock is undervalued. Key risks include weak cash flow trends and BetterHelp segment volatility. Upside depends on execution in integrated care and cost management.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
